174 related articles for article (PubMed ID: 38092371)
41. The clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma.
Du X; Li X; Zhang B; Hao Z; Gao Y; Jiang X; Yang Z; Chen Y
Ann Diagn Pathol; 2023 Aug; 65():152155. PubMed ID: 37172528
[TBL] [Abstract][Full Text] [Related]
42. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S
Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
[TBL] [Abstract][Full Text] [Related]
43. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
[TBL] [Abstract][Full Text] [Related]
44. Clinical significance of 9P21 gene combined with BAP1 and MTAP protein expression in diagnosis and prognosis of mesothelioma serous effusion.
Ma GY; Shi S; Wang P; Wang XG; Zhang ZG
Biomed Rep; 2022 Aug; 17(2):66. PubMed ID: 35815188
[TBL] [Abstract][Full Text] [Related]
45. Pleural mesothelioma classification update.
Beasley MB; Galateau-Salle F; Dacic S
Virchows Arch; 2021 Jan; 478(1):59-72. PubMed ID: 33475835
[TBL] [Abstract][Full Text] [Related]
46. Sarcomatoid mesothelioma diagnosed in a patient with mesothelioma in situ: a case report on morphologic differences after 9-month interval with details analysis of cytology in early-stage mesothelioma.
Yoshida M; Jimbo N; Tsukamoto R; Itoh T; Kawahara K; Mitsui S; Tanaka Y; Maniwa Y
Diagn Pathol; 2023 Nov; 18(1):126. PubMed ID: 38017544
[TBL] [Abstract][Full Text] [Related]
47. Molecular and immunohistochemical characterisation of mesothelioma of the tunica vaginalis
Anderson WJ; Sholl LM; Fletcher CDM; Schulte S; Wang LJ; Maclean FM; Hirsch MS
Histopathology; 2022 Jul; 81(1):65-76. PubMed ID: 35460532
[TBL] [Abstract][Full Text] [Related]
48. The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.
Hatem L; McIntire PJ; He B; Gogineni S; Ho M; Mathew S; Margolskee EM; Siddiqui MT; Rao RA
Diagn Cytopathol; 2019 Mar; 47(3):160-165. PubMed ID: 30520251
[TBL] [Abstract][Full Text] [Related]
49. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.
Hassan A; Prabhakaran S; Pulford E; Hocking AJ; Godbolt D; Ziad F; Pandita A; Wessels A; Hussey M; Russell PA; Klebe S
Pathology; 2024 May; ():. PubMed ID: 38789301
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
[TBL] [Abstract][Full Text] [Related]
51. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
Cigognetti M; Lonardi S; Fisogni S; Balzarini P; Pellegrini V; Tironi A; Bercich L; Bugatti M; Rossi G; Murer B; Barbareschi M; Giuliani S; Cavazza A; Marchetti G; Vermi W; Facchetti F
Mod Pathol; 2015 Aug; 28(8):1043-57. PubMed ID: 26022455
[TBL] [Abstract][Full Text] [Related]
52. Different Frequency and Clinical Role for MTAP Loss in Pleural and Peritoneal Mesothelioma.
Davidson B; Holth A; Hummel C; Flatmark K; Torgunrud A
Appl Immunohistochem Mol Morphol; 2024 May; ():. PubMed ID: 38812360
[TBL] [Abstract][Full Text] [Related]
53. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Kasai T; Kushitani K; Takeshima Y; Hiroshima K; Iwasaki A; Nabeshima K
Lung Cancer; 2023 Jan; 175():27-35. PubMed ID: 36442384
[TBL] [Abstract][Full Text] [Related]
54. Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion poor prognostic factors for preinvasive mesothelioma?
Nishikubo M; Jimbo N; Tanaka Y; Tachihara M; Itoh T; Maniwa Y
Virchows Arch; 2022 Aug; 481(2):307-312. PubMed ID: 35043235
[TBL] [Abstract][Full Text] [Related]
55. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
[TBL] [Abstract][Full Text] [Related]
56. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051
[TBL] [Abstract][Full Text] [Related]
57. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma.
Febres-Aldana CA; Chang JC; Jungbluth AA; Adusumilli PS; Bodd FM; Frosina D; Geronimo JA; Hernandez E; Irawan H; Offin MD; Rekhtman N; Travis WD; Vanderbilt C; Zauderer MG; Zhang Y; Ladanyi M; Yang SR; Sauter JL
Mod Pathol; 2024 Mar; 37(3):100420. PubMed ID: 38185249
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology.
Louw A; Lee YCG; Acott N; Creaney J; van Vliet C; Chai SM
Cytopathology; 2022 Jan; 33(1):84-92. PubMed ID: 34033161
[TBL] [Abstract][Full Text] [Related]
59. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
[TBL] [Abstract][Full Text] [Related]
60. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
Brcic L; Le Stang N; Gallob F; Pissaloux D; Sequeiros R; Paindavoine S; Pairon JC; Karanian M; Dacic S; Girard N; Churg A; Tirode F; Galateau-Salle F
Arch Pathol Lab Med; 2023 Mar; 147(3):313-322. PubMed ID: 35738002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]